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ANN KELLY PATRICK: Approaches Towards the Synthesis of Ketamine Metabolites 
(Under the direction of Dr. John Rimoldi) 
  
Major Depressive disorder (MDD) plagues society and stands at the forefront of 
research as MDD affects approximately 16% of the population. Pharmaceutical drugs 
including the selective serotonin reuptake inhibitors (SSRIs) have been used for MDD 
treatment and remain a popular option today. However, current antidepressant treatments 
have proven to be ineffective in just less than half of the patients. Research continues with 
the goal to better understand the mechanisms of the pathology of depression and to search 
for other treatment options. For example, the stress-neurogenesis hypothesis investigates 
the role of stress and decreased neuroplasticity within MDD.  
 Supporting the stress-neurogenesis hypothesis, the well-known anesthesia drug, 
ketamine, has shown antidepressant effects linked to glutamate neurotransmission and the 
successive downstream effects. However, the positive effects sustain after the rapid hepatic 
metabolism of ketamine leading scientists to explore key metabolites of ketamine and their 
effects on depressive symptoms.   
One of the ketamine metabolites, (2R, 6R)-hydroxynorketamine (HNK), has shown 
clinical benefits while decreasing the adverse side effects of ketamine in treatment-resistant 
MDD. The aim of this thesis research is to explore a simple oxidation protocol for the direct 
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Overview of MDD 
 
 Major Depressive disorder, commonly known as depression, affects more than 12% 
of men and 20% of women in the United States and more than 264 million people 
worldwide. MDD is characterized by significant mood changes associated with extreme 
sadness or irritability that lasts for longer than two weeks and is followed by 
psychophysiological changes such as alterations in eating, sleeping patterns, concentration, 
socialization, and sexual desires that can be accompanied by suicidal thoughts. Within the 
etiology of MDD lies ambiguity as depression correlates with both environmental and 
genetic factors. Genetic contribution was tested utilizing a twin study and revealed a 37% 
heritability; however, no one gene has been linked to MDD.1 With a lifetime prevalence of 
16%, depression stands with the highest prevalence of all mood disorders and the second 
most common mental illness.2 Physician office medical records document depression for 
9.3% of all patients.3 According to the World Health Organization, approximately 800,000 
people die each year due to suicide.4 Treatment of depression typically involves 
pharmacotherapy, psychotherapy, or supportive measures. With depression's high 
morbidity rates, MDD has significant economic and personal importance within society, 
guiding immense research efforts to improve the treatment of MDD. 
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History of Neuropathology, Theories, and Treatment of MDD 
 The dominant theory throughout the history of MDD remains the monoamine-
deficiency hypothesis. The monoamine-deficiency hypothesis targets the norepinephrine 
and serotonin systems as the basis for depression. Within this hypothesis, the current FDA 
approved treatments include MAO-Is, TCAs, and SSRIs. These drugs function to increase 
the concentration of norepinephrine or serotonin at the synaptic cleft.5 However, these 
treatments display unimpressive efficacy and therapeutic delays of 2 to 4 weeks. One-third 
to half of the population is reported to not respond to treatment for MDD, and consequently, 
this subset of the population is currently left without treatment.1-2 The prevalence of 
treatment-resistant depression alongside incomplete data concerning the monoamine 
hypothesis led to explorations of novel molecular pathways. The latency of clinical benefits 
directed most researchers to conclude that MDD is not a result of the direct impact of 
monoaminergic neurotransmitters such as norepinephrine and serotonin, but instead 
consists of downstream effects.  
 
The Stress Neurogenic Theory 
 A recent theory concerning the neuropathology of MDD is the stress-neurogenesis 
hypothesis. This theory involves stress and growth factors within the hypothalamic-
pituitary-adrenal (HPA) axis. Stress is processed in the cerebral cortex and relayed in the 
hypothalamus, causing a release of corticotropin-releasing hormone (CRH) onto anterior 
pituitary receptors that in response secrete adrenocorticotropic hormone (ACTH) that 
signal the adrenal cortex to release cortisol into the blood. The increase in cortisol signals 
the hypothalamus to decrease CRH production as a feedback inhibition to maintain 
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homeostasis. Increased levels of cortisol in the blood and CRH in the cerebral spinal fluid 
have been reported in individuals with MDD, and disruptions within the feedback 
inhibition of the HPA axis have been shown in severely depressed individuals. Moreover, 
an increase in cortisol is linked to a decrease in Brain-Derived Neurotropic Factor (BDNF). 
BDNF is a neurotrophic peptide that is essential for axonal growth, neuronal survival, and 
synaptic plasticity. The decrease in BDNF, ultimately caused by stress, stunts neurogenesis 
in the hippocampus, amygdala, and prefrontal cortex, causing atrophy of these critical 
limbic structures. The degradation of the critical limbic structures could be accountable for 
the symptomology of MDD. BDNF appears as a prominent link to MDD as decreased 
BDNF levels have been found in patients who committed suicide, and increased levels of 
BDNF have resulted from current antidepressant drugs and electroconvulsive therapies.1-2  
 With the alternate theory of the stress-neurogenesis hypothesis, the major 
excitatory neurotransmitter, glutamate, has been postulated as an option to offset the 
neuronal loss. The glutamatergic system induces neuroplasticity with the building of 
synapses to aid in learning and the retrieval of memories.5  
 
Ketamine, Its Metabolites, and Potential Antidepressant Use 
 Ketamine, a short-acting anesthesia drug, acts as a glutamatergic agent and shows 
promise in the area of MDD treatment. The drug is commonly used for general anesthesia, 
especially in pediatric anesthesia cases. At sub-anesthesia doses, the drug generates pain 
relief, classifying the drug as an analgesic. At high doses, users report out of body 
experiences sometimes coupled with delirium and symptoms of psychosis. The drug is a 
noncompetitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist causing 
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interferences within the glutamatergic system. The drug affects other receptors such as 
muscarinic, nicotinic, cholinergic, and opioid receptors. A variety of downstream effects 
commonly associated with antidepressant effects have been reported, including increases 
in BDNF and mTOR protein levels, a mammalian kinase encoded by the mTOR gene that 
is the mammalian target of rapamycin. The research proposes that the excitatory 
neurotransmitter glutamate increases within the synaptic slept due to increased glutamate 
release and AMPA receptor expression. The increase of glutamate provokes an increase in 
BDNF and mTOR, triggering extended synaptic growth. The drug shows anti-depressive 
benefits within two hours, and the effects can continue for a week.6 The R enantiomer is 
shown to be the source of the sustained antidepressant effects.7 The proposed signaling 
cascade links ketamine to antidepressant effects via the stress-neurogenesis hypothesis. 
However, ketamine's high abuse liability and psychotomimetic (psychotogenic) effects 
limit its clinical benefits as an antidepressant for everyday use.6 When researchers 
examined patients reporting anti-depressive effects of ketamine, they found low 
concentrations of ketamine and higher concentrations of its metabolites.8 
 




 The major metabolites of ketamine are depicted in Figure I. Exploring metabolites 











Ketamine (1) Norketamine (2) (2R,6R)-Hydroxynorketamine (3)
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benefits with ketamine, yet without many of the negative effects. The N-demethylation of 
ketamine yields norketamine (2), which is thereafter hydroxylated to produce multiple 
hydroxynorketamines. Particularly, the stereoisomer, (2R,6R)-hydroxynorketamine 
[(2R,6R)-HNK: 3], has shown improved clinical efficacy alongside increased therapeutic 
windows in multiple animal behavioral tests. The metabolite (2R,6R)-HNK reduces 
psychotic effects compared to the parent drug, lowering the abuse liability.9 Lumsden 
associates ketamine’s abuse liability and adverse behavioral effects to NMDAR inhibition. 
The metabolite (2R,6R)-HNK functions differently than ketamine as it does not bind nor 
inhibit NMDA receptors at antidepressant-relevant concentrations (10 "L).10 Also, 
(2R,6R)-HNK did not inhibit !-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors. Lumsden reported that dissociation effects were experienced with 30 
mg/kg doses of ketamine, while doses of up to 375 mg/kg of (2R,6R)-HNK showed no 
effect. Also, he reported that unlike ketamine, mice did not self-administer (2R,6R)-HNK 
at anti-depressant doses.10 The exact mechanisms of (2R,6R)-HNK are unknown, but 
Fukumoto connected the antidepressant effects to the activity-dependent release of BDNF 
and mTOR signaling that is mediated by the stimulation of voltage dependent calcium 
channels.11 The release of BDNF and mTOR signaling increased synaptogenesis and 
synaptic function in the medial prefrontal cortex. Zanos revealed group II metabotropic 
glutamate receptor subtype 2 (mGlu2) inhibition via (2R, 6R)-HNK to enhance cortical 
quantitative EEG (qEEG) power in mice, a relevant marker to test antidepressant-relevant 
actions.9 The increased AMPA activation, BDNF activity, mGlu2 receptor inhibition, and 
resulting downstream pathways, including mTOR, are thought to be the source of 
synaptogenesis, generating the antidepressant effects of (2R,6R)-HNK. Moreover, not 
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being processed in the liver, (2R,6R)-HNK avoids many drug interactions. The metabolite 
(2R,6R)-HNK provides a plausible drug of choice to study with promising data in the 
ongoing search for better treatment of MDD, specifically with treatment-resistant 
depression. Due to the increased interest surrounding (2R,6R)-HNK, the objective of this 
thesis research was to explore a novel route for the synthesis of (2R,6R)-HNK to improve 
overall reaction yields and to reduce cost and number of synthetic steps. 
 
  7 
RESULTS AND DISCUSSION 
 
With the promise of progress in antidepressant pharmacotherapy, novel approaches 
for the synthesis of (2R,6R)-HNK (3) were considered based on prior synthesis. Two 
chemical syntheses of compound 3 have been reported to date. The first synthesis was 
reported by Morris et. al in 2017 and relied on a modification of an original route for 
ketamine synthesis (Figure II).12 Commercially available ketone 4 was converted in a 5-
step sequence to enantiopure R-norketamine (5) through initial bromination of the ketone, 
subsequent condensation with ammonium hydroxide, and a thermal rearrangement to 
afford racemic norketamine in 44% overall yield. Chiral resolution using pyroglutamic acid 
provided 5 in gram scale, which was subjected to a Rubottom oxidation to install the α-
keto-alcohol with the desired stereochemistry and an excellent diastereoselective ratio. A 
series of amine protection/deprotection protocols were also included in the synthesis.  
 
Figure II:  Morris synthesis of (2R,6R)-HNK (3) 
 
In 2017, the Corey group reported an alternate synthesis of 3 employing as a key step the 
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Jacobsen’s salen-type catalyst (catalyst B, Figure III) and NaOCl as oxidant.13 
Regioselective ring opening of the epoxide with titanium isopropoxide and 
trimethylsilylazide followed by a Dess−Martin periodinane oxidation afforded enantiopure 
7 which was reduced to the corresponding amine and converted to 3 utilizing a Rubottom 
oxidation and similar reaction sequences as first reported by Morris.  
 
 
Figure III:  Corey’s synthesis of (2R,6R)-HNK (3) 
 
Each reported synthesis relies on a late-stage Rubottom oxidation of key intermediate 
norketamine (2), with this oxidation method requiring the use of an alkylithium, low 
reaction temperatures, peroxybenzoic acid and a fluoride source. Our approach was to 
synthesize sufficient quantities of racemic norketamine and to use this intermediate to 
explore an inexpensive oxidation protocol for the synthesis of hydroxynorketamine 
metabolites, namely, the α-hydroxylation reaction of ketones with dimethyl sulfoxide 
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Synthetic Approach and Specific Aims 
The specific aims of this thesis research project are: 
1) To synthesize sufficient quantities of norketamine (2) using established procedures. 
2) To explore the potential utility of the I2- or NBS-catalyzed α-hydroxylation reaction of 
norketamine with dimethylsulfoxide (DMSO).14  
 
This oxidation protocol is attractive insofar as DMSO acts as an oxidant, oxygen source, 
and solvent. Moreover, the reaction conditions are mild and reagents are inexpensive, in 
comparison the Rubottom oxidation protocol. This sequence would provide direct access 
to hydroxylated norketamine analogs (stereochemistry notwithstanding). 
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Specific Aim 1:  3-Step Synthesis of Norketamine (2) 
 
Step 1 (Palladium Catalyzed Arylation Reaction): We initiated the synthesis by using a 
palladium-catalyzed ketone arylation reaction between 1-bromo-2-chlorobenene (8) and 
cyclcohexanone (9) to afford the desired product, 2-(2-chlorophenyl)cyclohexan-1-one 
(10; Scheme 1). This specific reaction was reported by Willis in 2004 as an adaptation of 
the Buchwald arylation reaction and represents an efficient method for the creation of 
alpha-arylated ketones.15 The reaction was performed in toluene at 80 oC using 0.5 mol % 
of Pd2-(dba)3, 1.2 mol % of Xantphos, and Cs2CO3 affording product 10 in 51% yield 
(unoptimized). The spectroscopic data (1H NMR, 13C NMR, MS) matched the literature 
reported values and the product yields were consistent when repeated reactions were 
performed. 
 
Scheme 1: Synthesis of 2-(2-chlorophenyl)-cyclohexan-1-one (10) 
 
Step 2 (Aliphatic Nitration Reaction): In 2017, Zhang et al reported a 4-step synthesis of 
ketamine (1), employing as a key step, a copper-assisted direct nitration of aryl and alkyl 
substituted cyclic ketones with ceric ammonium nitrate [(NH4)2Ce(NO3)6: CAN] (Scheme 
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functions: as a Lewis acid (promoting enolization of ketone starting material), an oxidant, 
and a nitrating reagent. Although the role of copper had not been fully elucidated for this 
reaction, it is believed to stabilize an intermediate radical species. This reaction was 
conducted using the reported reaction conditions (conventional heating in oil bath) in 




Scheme 2:  Synthesis of 2-(2-chlorophenyl)-2-nitrocyclohexan-1-one (11) 
 
We utilized identical experimental conditions for the nitration reaction using the 
conventional heating method as reported by Zhang, who optimized reaction conditions for 
the synthesis of nitrated products from a small library of alpha-substituted cyclic ketone 
precursors. It is important to note Zhang’s reported yields of nitrated products (using 14 
different substrates) were modest and varied with an average yield of approximately 55%.   
The reaction conditions for the synthesis of 11 used 1, 2-dichloroethane (DCE) as a solvent 
with the addition of 10, Cu(OAc)2 and (NH4)2Ce(NO3)6 in a sealed tube under an argon 
atmosphere and heating in an oil bath at 80 oC. When the reaction was repeated using these 
conditions, the desired product of the reaction, 2-(2-chlorophenyl)-2-nitrocyclohexan-1-
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days), and higher reaction temperatures (100 oC). Alternate commercial sources of CAN 
were also used in separate reactions to rule out reagent quality issues, but without success.   
It is not clear why the nitration reaction failed in our hands when conducted using identical 
reaction conditions as reported in the literature. Notwithstanding, the literature yield for 
the conversion of 10 to 11 was reported to be 51% after product purification by silica gel 
column chromatography. We then turned our efforts to using microwave irradiation rather 
than conventional heating to provide some insight. We utilized a Biotage Initiator 
Microwave Synthesizer (2.45 GHz) and performed the nitration reaction using similar 
reaction conditions reported under conventional heating. Since microwave irradiation 
allows reaction times to exponentially decrease, we anticipated 10-20 minutes of 
microwave heating would suffice. Using DCE as a solvent was appropriate for conducting 
the microwave heating (The heating performance of a solvent under microwave irradiation 
is dependent on its ability to convert electromagnetic energy into heat and is related to the 
solvent dielectric constant). In initial experiments, microwave irradiation was applied to 
the reaction mixture in 10-minute intervals with reaction monitoring and required 50 
minutes of microwave heating at 80 °C. Each 10-minute interval was preceded with pre-
stirring (2 min) due to a concern with inconsistency of stirring throughout the microwave 
irradiation timeframe, based on visual inspection of the reaction mixture. Although not 
fully optimized, reactions performed under these conditions afforded the nitration product 
11, albeit in low yields (average yield 22%).   
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Step 3 (Nitro Reduction) 
 
Scheme 3: Synthesis of 2-(2-chlorophenyl)-2-aminocyclohexan-1-one (norketamine; 2) 
 
This final step involved the reduction of the nitro group to an amine group with zinc powder 
and the weak acid solvent acetic acid (Scheme 3). This resulted in a 69% product yield 
(isolated as free base), and the spectroscopic data matched the literature reported values for 
norketamine.  Around the time the three-step synthesis of norketamine was completed, a 
commercial vendor (Advanced ChemBlocks Inc.) began to offer this rare compound in 
gram quantities at a reasonable price, and one gram was purchased in order to explore the 

















  14 
Specific Aim 2:  Exploring the potential of the DMSO oxidation of norketamine 
In order to evaluate the potential of applying the DMSO oxidation to the substrate 
norketamine, initial amine group protection was warranted.  Treatment of 2 with di-tert-
butyl dicarbonate and potassium carbonate in toluene yielded N-Boc protected amine 
derivative 12 in 85% yield (Scheme 4), with spectroscopic data consistent with the data 
reported by Corey for the same compound produced as an intermediate in his synthesis.13 
 
Scheme 4: Synthesis of tert-butyl (1-(2-chlorophenyl)-2-oxocyclohexyl)carbamate (12) 
 
Preliminary DMSO oxidation studies were performed on compound 12 using either I2 or 
N-bromosuccinimide (NBS) as catalysts. Standard reaction conditions reported for this 
conversion were optimized for a-methine carbonyl containing substrates and include the 
following: ketone (0.5 mmol), NBS or I2 (20 mol %), DMSO (1 mL), at 100 °C, under air 
for 24 h.14 When the reaction was performed using either NBS or I2, only norketamine 2 
was isolated, suggesting the instability of the N-Boc protecting group under these reaction 
conditions. In order to circumvent this problem, a more stable amine protecting group was 
selected, namely a methylcarbamate group. Treatment of 2 with methylchloroformate and 
sodium carbonate in toluene yielded carbamate 13 in an 84% yield, Reaction of 13 with I2 
(20 mol %) in DMSO at 100 °C, under air for as long as 96 hours did not result in 















  15 
with NBS (20 mol %) in DMSO at 100 °C, under air for 4 days afforded a hydroxylated 
product 14 in 37% yield (Scheme 5).  
 
Scheme 5: Synthesis of carbamate 13 and its subsequent DMSO oxidation 
 
The mechanism of DMSO oxidation of ketones catalyzed by iodine or NBS has been 
proposed and is believed to operate by way of an initial electrophilic halogenation of the 
substrate ketone yielding an α-halogen carbonyl A followed by an SN2 reaction with the 
nucleophilic oxygen atom of DMSO yielding an intermediate B/C (Figure V). Protonation 
affords the hydroxylation product concomitant with the release of dimethyl sulfide and 
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Figure V:  Proposed mechanism of NBS or I2 catalyzed DMSO oxidation of ketones14 
 
Due to unforeseen circumstances related to Covid-19, this oxidation reaction was only 
performed once. The purified product was analyzed by 1H -NMR, and the data appear 
encouraging. But the NMR data is more complex than anticipated, which is suggestive of 
a product containing a diastereomeric mixture of 6-hydroxy isomers. Further NMR 
analysis needs to be conducted on the product from the reaction.  
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Conclusions 
 
A three-step synthesis of norketamine (2) was accomplished in order to produce 
starting material for exploring its subsequent I2- or NBS-catalyzed DMSO oxidation. 
Although the results of the DMSO oxidation reaction of carbamate protected norketamine 
was encouraging, further studies are warranted to optimize reaction conditions and to 
confirm both the regiochemistry of hydroxylation, and the relative stereochemistry of the 
hydroxylated product. The use of microwave irradiation may be beneficial in the DMSO 
oxidation reaction, based on the positive results obtained from the nitration experiments 
described using CAN.   
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MATERIALS AND METHODS 
 
General Methods: 
 Commercially available solvents and reagents were purchased from either Sigma 
Aldrich Inc., Fisher Scientific, or Alfa Aesar Chemicals. Glassware used for anhydrous 
reactions was flame or oven dried and placed under vacuum and purged with argon gas.   
 
Chromatographic Purification: 
 Thin layer chromatography and UV light source was used to monitor the reaction 
progress with references to the starting materials and products using aluminum plates 
coated with silica gel and a phosphor. Phosphomolybdic acid was used to stain the TLC 
plates when non-UV active compounds were analyzed.  
 Silica gel column chromatography was performed using 220-440 mesh and 
appropriate mobile phase solvents.  Fractions were collected and monitored by comparing 
sample from test tubes to crude and reference materials using TLC. 
 
Mass Spectrometry: 
 After TLC confirmed the presence of the desired product, mass spectroscopy data 
was obtained to confirm the desired molecular weight of the product.  A Waters ZQ single 
quadrupole mass spectrometer was employed using an ESI source to monitor MH+ parent 
ions or their associated MNa+ adducts.  
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NMR Analysis: 
 NMR spectral data was obtained using a Bruker Ascend™ 400 MHz NMR 
spectrometer, and samples were prepared using deuterated chloroform (CDCl3) as the 
solvent. Each signal is defined relative to TMS. Proton (1H), carbon (13C), and DEPT-135 
NMR spectra were acquired.  The TOPSHIM function was utilized to adjust the probe to 
the sample. Mestrelab software (MNova) was utilized to analyze raw data. The baseline 






 Cesium carbonate (9.10 mg, 27.94 mmol) was added to a 100 mL oven dried round 
bottom flask charged with Pd2 (dba)3 (59 mg, 0.064 mmol) and Xantphos (88.6 mg, 0.153 
mmol) under a blanket of argon gas. The flask was vacuum purged and refilled with argon 
gas three times. Anhydrous 1,4-dioxane (15 mL) was added to the flask, and under argon 
gas, freshly redistilled cyclohexanone (9, 2.50 mg, 2.64 mL, 25.48 mmol) and 1-bromo-2-
chlorobenzene (8, 2.439 g, 1.49 mL, 12.74 mmol) were added. The reaction was heated at 
100 °C for 24 hours. In the first 10 minutes of heating, the reaction mixture changed from 
a red to a yellow color, and after 25 minutes, it changed to a green color. The final color 
was a dark brown. After 24 hours, the sample was cooled to room temperature and then 
diluted with diethyl ether (50 mL) and washed with distilled H2O (100 mL). Using a 
separation funnel, the organic layer containing the product was extracted with diethyl ether 
(3 x 100 mL). The organic layer was washed with brine solution (100 mL), dried over 
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MgSO4, filtered using gravity filtration, and concentrated under vacuum. The catalyst 
created a sticky product that was slightly water soluble. The product was purified using a 
silica gel column and a mobile phase of 10% ethyl acetate/hexanes as an eluent to afford 
the purified product of 10 as a white solid (1.4 g, Yield: 51%). 1H NMR (400 MHz, 
Chloroform-d) δ 7.40 (dd, J = 7.8, 1.4 Hz, 1H), 7.32 – 7.20 (m, 3H), 4.14 (dd, J = 12.6, 5.4 Hz, 
1H), 2.63 – 2.49 (m, 2H), 2.36 – 2.15 (m, 2H), 2.13 – 1.98 (m, 2H), 1.98 – 1.76 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 208.72, 136.80, 134.21, 129.46, 129.38, 128.13, 126.78, 77.45, 77.14, 76.82, 





For the conventional heating reaction, 2-(2-chlorophenyl)-cyclohexan-1-one (10, 
59.3 mg, 0.284 mmol), anhydrous Cu(OAc)2 (99% purity, 11.1 mg, 0.061 mmol), and 
(NH4)2Ce(NO3)6 (290 mg, 0.529 mmol) were added into a tube with 1, 2-dichloroethane (4 
mL).  The reaction mixture was vortexed, then a stir bar was added, the cap was sealed, 
and finally, the reaction mixture was stirred in a preheated oil bath at 80°C for 24 hours. 
The reaction was monitored by TLC with a mobile phase consisting of 20% ethyl 
acetate/hexanes and no product was observed even with prolonging the reaction time for 4 
days and also by increasing the reaction temperature to 100°C. 
 Alternatively, we attempted a microwave irradiation reaction using a 2.45 GHz 
Biotage Microwave Initiator employing the same combination of reagents described above.  
Microwave radiation was applied to the reaction mixture in 10 minute intervals for 50 
minutes at 80°C. Each 10-minute interval was preceded with pre-stirring (2 min). The 
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reaction was monitored by TLC with a 20% ethyl acetate/hexanes solvent system. After 50 
minutes of the reaction, the reaction mixture was diluted with 30 mL of ethyl acetate, dried 
over anhydrous sodium sulfate and the organic portion was filtered one more time, 
evaporated under a reduced pressure using a rotary evaporator and the resultant crude 
viscous dark yellow residue was purified, using preparative TLC (silica gel, 500-micron 
thickness) with 20:80 ethyl acetate/hexanes as an eluent, to afford 16 mg of the desired 
product 11 as a pale yellow solid (yield: 22%).  1H NMR (400 MHz, Chloroform-d) δ 7.48 – 
7.10 (m, 4H), 3.14 – 2.55 (m, 3H), 2.03 – 1.50 (m, 5H). 13C NMR (101 MHz, CDCl3) δ 199.15, 
135.08, 132.04, 131.77, 131.01, 129.04, 127.42, 101.40, 40.62, 36.51, 27.16, 21.92. (ESI) m/z 
calculated for C12H12NO3ClNa [M+Na]+ 276.04, found 276.05. 
 
2-(2-chlorophenyl)-2-aminocyclohexan-1-one (norketamine; 2) 
 
 Zinc powder (4 x 20 mg; 0.3 mmol; in 30 min intervals) was added to a solution of 
2-(2-chlorophenyl)-2-nitrocyclohexan-1-one (13 mg, 0.05 mmol) in AcOH (1.0 mL) under 
a blanket of argon. The reaction mixture was stirred for 12 hours and filtered.  The filtrate 
was concentrated and the residue diluted with dichloromethane and washed with a 
saturated aqueous sodium bicarbonate solution (5.0 mL). The aqueous phase was extracted 
with dichloromethane (3×4 mL) and the combined organic layers were dried over 
anhydrous sodium sulfate, filtered and the solvent was removed under vacuum yield 8 mg 
(69%) of product. 1H NMR (400 MHz, Chloroform-d) δ 7.70 (d, J = 7.8 Hz, 1H), 7.41 – 
7.30 (m, 2H), 7.30 – 7.22 (m, 1H), 2.81 (d, J = 11.7 Hz, 2H), 2.64 – 2.53 (m, 1H), 2.47 
(dd, J = 9.2, 3.9 Hz, 1H), 2.02 (d, J = 6.2 Hz, 1H), 1.89 – 1.59 (m, 3H). 13C NMR (101 
MHz, CDCl3) δ 212.46, 139.66, 133.14, 131.07, 129.19, 128.57, 127.29, 77.39, 77.08, 
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76.76, 66.62, 41.08, 39.03, 28.54, 22.17. (ESI) m/z calculated for C12H13NO3Cl [M+H]+ 
224.08, found 224.0. 
 
tert-Butyl (1-(2-chlorophenyl)-2-oxocyclohexyl)carbamate (12) 
To a solution of norketamine (2; 100 mg, 0.39 mmol) in toluene (3 mL) was added 
potassium carbonate (160 mg, 1.2 mmol) and di-tert-butyl dicarbonate (126 mg, 0.58 
mmol). The reaction was heated to 80 °C and stirred for 20 hours. The reaction was cooled, 
extracted with ethyl acetate and washed with water. The organic layer dried over anhydrous 
sodium sulfate, filtered, and the solvent removed to afford a crude white solid.  Purification 
by silica gel chromatography (20% ethyl acetate in hexanes) gave 124 mg (Yield: 85%) of 
12 as a crystalline white solid. 1H NMR (400 MHz, Chloroform-d) δ 7.87 (d, J = 8.0 Hz, 
1H), 7.36 (dt, J = 7.9, 2.0 Hz, 2H), 7.31 – 7.24 (m, 1H), 6.64 (s, 1H), 3.86 (d, J = 14.4 Hz, 
1H), 2.50 – 2.26 (m, 2H), 2.07 (td, J = 5.7, 2.7 Hz, 1H), 1.91 – 1.57 (m, 4H), 1.33 (s, 9H).  
(ESI) m/z calculated for C17H23ClO3N [M+H]+ 324.14; found, 324.10. 
 
Methyl (1-(2-chlorophenyl)-2-oxocyclohexyl)carbamate (13) 
To a mixture of norketamine (2; 100 mg; 0.45 mmol) in anhydrous toluene (3 mL) 
and anhydrous Na2CO3 (150 mg), a solution of methyl chloroformate (100 µL) in 
anhydrous toluene (300 µL) was added. After heating under reflux for 3 h, the reaction 
mixture was cooled to room temperature and washed subsequently with water, 10% 
Na2CO3, and water. The product was diluted with ethyl acetate, dried with anhydrous 
MgSO4, filtered and concentrated under reduced pressure to yield 106 mg (yield 84%) of 
13 as a white solid. 1H NMR (400 MHz, Chloroform-d) δ 7.96 – 6.64 (m, 5H), 3.44 (s, 
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3H), 2.48 – 1.43 (m, 8H). 13C NMR (101 MHz, CDCl3) δ 208.87, 154.49, 134.67, 133.88, 
131.66, 131.03, 129.54, 126.21, 77.37, 77.05, 76.73, 67.17, 51.63, 39.35, 38.38, 30.80, 
22.33.   (ESI) m/z calculated for C14H17ClNO3 [M+H]+ 282.08 found, 282.14. 
 
Methyl (1-(2-chlorophenyl)-3-hydroxy-2-oxocyclohexyl)carbamate (14) 
Compound 13 (28 mg, 0.1 mmol), iodine crystals (6 mg, 0.02 mmol; 20 mol%), 
and DMSO (1 mL) were added to a 5 mL reaction flask fitted with an air-condenser. The 
mixture was stirred at 60 °C for 24 hours and monitored by TLC. There was no change in 
the reaction even after 3 days and also at higher temperatures of up to 100 °C. After cooling 
to room temperature, the solution was diluted with ethyl acetate (10 mL) and washed with 
0.1 M Na2S2O3 (5 mL) aqueous solution to quench the unreacted iodine, extracted with 
ethyl acetate (3×5 mL), and evaporated under vacuum and unreacted starting material 
collected.  Substituting iodine crystals for N-bromosuccinimide (5 mg, 0.02 mmol; 20 
mol%) and performing the reaction under the same conditions resulted a reaction showing 
the formation of a new product by TLC which showed a lower Rf value compared to the 
starting material. The reaction was cooled, diluted with ethyl acetate and washed with 
water. The organic layer was dried over sodium sulfate, the solvent removed under reduced 
pressure to yield a white solid. Purification by silica gel column chromatography (30% 
ethyl acetate in hexanes) afforded 11 mg (Yield: 37%) of compound tentatively identified 
as 14. 1H NMR (400 MHz, Chloroform-d) δ 7.49 – 7.01 (m, 5H), 5.77 (s, 1H), 4.04 (s, 1H), 
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